Defining the benefits of desensitization therapy

Transplantation

Volumn 95, Issue 6, 2013, Pages

  Jordan, Stanley C ^a   Vo, Ashley ^a   Lai, Chih Hung ^a   Reinsmoen, Nancy ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN; PLACEBO; RITUXIMAB; ALLOANTIBODY; HLA ANTIGEN; MONOCLONAL ANTIBODY;

ANTIBODY SPECIFICITY; CLINICAL EFFECTIVENESS; COMPLEMENT DEPENDENT CYTOTOXICITY; DESENSITIZATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; GENE FREQUENCY; HAPLOTYPE; HISTOCOMPATIBILITY; HLA MATCHING; HUMAN; IMMUNOMODULATION; LETTER; LOW DRUG DOSE; PRIORITY JOURNAL; BLOOD; FEMALE; HYPERSENSITIVITY; IMMUNOLOGY; KIDNEY TRANSPLANTATION; MALE; NOTE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HLA ANTIGENS; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULINS, INTRAVENOUS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE;

EID: 84877623607     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182845fe1     Document Type: Letter

References (11)

1. Alachkar N, Lonze BE, Zachary AA, et al. Infusion of high-dose intravenous immu-noglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients. Transplantation 2012; 94: 165.
2. Marfo K, Ling M, Bao Y, et al. Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients. Transplantation 2012; 94: 345.
3. Lai CH, Cao K, Ong G, et al. Antibody testing strategies for deceased donor kidney transplantation after immunomodulatory therapy. Transplantation 2011; 92: 48.
4. Vo A, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
5. Vo A, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 1095.
6. Reinsmoen N, Lai C-H, Vo A, et al. Evolving paradigms for desensitization in managing broadly HLA sensitized transplant candidates. Discov Med 2012; 13: 267.
7. Kahwaji J, Sinha A, Toyoda M, et al. Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin. Clin J Am Soc Nephrol 2011; 6: 2894.
8. Shehata N, Palda V, Meyer R, et al. The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline. Transf Med Rev 2010; 24: 7.
9. Marfo K, Lu A, Ling M, et al. Desensitiza-tion protocols and their outcomes. Clin J Am Soc Nephrol 2011; 6: 922.
10. Montgomery RA, Lonze B, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318.
11. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin (IVIG) as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15: 3256.